protein expression analysis(Eli Lilly and Company)은 Leukemia 표적 치료제로, Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting of cell cycle and apoptotic pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 19.2% (ClinicalTrials.gov NCT03386721). 차별점: unique pharmacological probe and lead compound that functions through direct modulation of FOXO3, offering a new direction for.
Leukemia
Colorectal Cancer
Discontinued
unique pharmacological probe and lead compound that functions through direct modulation of FOXO3, offering a new direction for
targeting of cell cycle and apoptotic pathway
apoptosis, and invasion pathways in colorectal cancer
biomarker associated with adverse clinical outcomes in HCC
escape latency in the IH group significantly increased with prolonged exposure duration (2W: 21
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
protein expression analysis(Eli Lilly and Company)은 Leukemia 표적 치료제로, Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting of cell cycle and apoptotic pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 19.2% (ClinicalTrials.gov NCT03386721). 차별점: unique pharmacological probe and lead compound that functions through direct modulation of FOXO3, offering a new direction for.
Leukemia
Colorectal Cancer
Discontinued
unique pharmacological probe and lead compound that functions through direct modulation of FOXO3, offering a new direction for
targeting of cell cycle and apoptotic pathway
apoptosis, and invasion pathways in colorectal cancer
biomarker associated with adverse clinical outcomes in HCC
escape latency in the IH group significantly increased with prolonged exposure duration (2W: 21
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.